; and (C) for communications relating to a drug, biological product, or device that has not been approved for marketing under section 505, 510, or 515 of this Act or section 351 of the Public Health Service Act, or relating to a use of a drug, biological product, or device that has not been so approved, the manufacturer and sponsor make no claims that such product or use has been demonstrated to be safe or effective. (3) Scientific exchange described The scientific exchange of information under paragraph (2) may include— (A) dissemination of scientific findings in scientific or lay media; (B) publication of results of scientific studies; (C) letters to the editor in defense of public challenges; (D) communications at scientific or medical conferences or meetings; (E) dissemination of medical or scientific publications, reference texts, or clinical practice guidelines; (F) communication, both proactive and reactive, of information regarding a manufacturer’s research and development efforts; (G) communication, both proactive and reactive, of scientific, medical, or technical information or findings, including communication of such information by personnel in scientific, medical, or clinical development departments of manufacturers